Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. [Corrigendum]
Nanda K, Moss AC.Clinical Pharmacology: Advances and Applications. 2012, 4:41–50.The authors apologize for errors on Tables 1, 2, and 3.Table1Citation 40, Hussain et al, should have been citation 44, Shire US Inc.Table 2Lichtenstein et al data, the confidence interval (CI) of the odds...
Guardado en:
Autores principales: | Nanda K, Moss AC |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/03009643a99b4fe0be7bb0f9e8f3d55c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
por: Nanda K, et al.
Publicado: (2012) -
Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
por: Maconi G, et al.
Publicado: (2021) -
Identification of Pharmacological Autophagy Regulators of Active Ulcerative Colitis
por: Peishan Qiu, et al.
Publicado: (2021) -
Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
por: Jakate A, et al.
Publicado: (2019) -
Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven®)
por: Bartosh NS, et al.
Publicado: (2013)